Tilray Medical publishes research on pharmacokinetics of THC, CBD formulations

Tilray (TLRY) Medical, a division of Tilray Brands, announced the publication of a scientific study. This new research focuses on comparing the bioavailability of different cannabinoid formulations, taking a step forward in our understanding of medical cannabis. This pilot study shows that oral administration of Tilray THC:CBD extract formulation achieved higher THC and CBD concentrations within a shorter timeframe compared to the oromucosal delivery of nabiximols. These findings may have significant implications for clinical populations using these formulations therapeutically.